Monoclonal Gammopathy of Thrombotic Significance
暂无分享,去创建一个
[1] I. Olafsson,et al. Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do , 2022, Blood.
[2] A. Khorana,et al. Abnormal Metaphase Cytogenetics Predicts Venous Thromboembolism in Myeloma: Derivation and Validation of the PRISM Score. , 2022, Blood.
[3] T. Rebbeck,et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. , 2022, The Lancet. Haematology.
[4] T. Tvedt,et al. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results , 2022, Haematologica.
[5] T. Renné,et al. Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy , 2021, Haematologica.
[6] J. Farber,et al. Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review , 2021, Frontiers in Immunology.
[7] I. Olafsson,et al. Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study , 2021, Blood.
[8] I. Olafsson,et al. Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research - the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) , 2021, Blood.
[9] G. Caimi,et al. Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders. , 2021, Microvascular research.
[10] S. Kristensen,et al. Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. , 2021, Thrombosis research.
[11] S. Berentsen. How I Treat Cold Agglutinin Disease. , 2021, Blood.
[12] B. Hunt,et al. Antiphospholipid Syndrome with Monoclonal Gammopathy—A Mechanism for Recurrent Thrombosis? , 2021, Thrombosis and Haemostasis.
[13] A. Khorana,et al. Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score , 2020 .
[14] G. Rapaccini,et al. Cryoglobulins: Identification, classification, and novel biomarkers of mysterious proteins , 2020, Advances in Clinical Chemistry.
[15] M. Cahill,et al. Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance , 2020, British journal of haematology.
[16] L. Arend,et al. Crystalglobulin-associated nephropathy presenting as MGRS in a case of monoclonal B-cell lymphocytosis: a case report , 2020, BMC Nephrology.
[17] J. Strnad,et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma , 2020, Molecular Cancer Therapeutics.
[18] J. Fryzek,et al. Increased risk of thrombotic events in cold agglutinin disease: A 10‐year retrospective analysis , 2020, Research and practice in thrombosis and haemostasis.
[19] S. Berentsen. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia , 2020, Frontiers in Immunology.
[20] U. Jäger,et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. , 2019, Blood reviews.
[21] M. Dimopoulos,et al. Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process , 2019, TH Open.
[22] M. Vekemans,et al. Crystalcryoglobulinemia-induced kidney disease , 2019, Clinical Lymphoma Myeloma and Leukemia.
[23] A. Dispenzieri,et al. Monoclonal gammopathy‐associated thrombotic microangiopathy , 2019, American journal of hematology.
[24] S. Berentsen,et al. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. , 2019, Blood advances.
[25] S. Berentsen,et al. Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence? , 2019, Case reports in hematology.
[26] U. Jäger,et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. , 2019, Blood.
[27] V. D’Agati,et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group , 2018, Nature Reviews Nephrology.
[28] K. Ramasamy,et al. Multiple Myeloma Treatment Is Associated with Enhanced Platelet Reactivity , 2018, Blood.
[29] A. Hüttmann,et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. , 2018, Blood advances.
[30] D. Hose,et al. Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance , 2018, Leukemia.
[31] K. Yazdanbakhsh,et al. Hemolysis and immune regulation , 2018, Current opinion in hematology.
[32] G. Caimi,et al. Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS). , 2017, Clinical hemorheology and microcirculation.
[33] C. Rafat,et al. Complement-dependent, monoclonal gammapathy-associated thrombotic microangiopathy. , 2017, Kidney international.
[34] D. Dingli,et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia , 2017, American journal of hematology.
[35] Yan Li,et al. Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients. , 2017, Lung cancer.
[36] Jialin Teng,et al. IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report , 2017, BMC Immunology.
[37] Taura L. Barr,et al. Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation , 2017, Brain injury.
[38] J. Shatzel,et al. Syndromes of Thrombotic Microangiopathy. , 2017, The Medical clinics of North America.
[39] F. Fervenza,et al. Thrombotic microangiopathy associated with monoclonal gammopathy. , 2017, Kidney international.
[40] R. Luqmani,et al. Cryofibrinogenaemia—a neglected disease , 2016, Rheumatology.
[41] C. Marosi,et al. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis , 2016, Thrombosis and Haemostasis.
[42] [Venous thromboembolism in multiple myeloma]. , 2016, Nihon rinsho. Japanese journal of clinical medicine.
[43] V. Gudnason,et al. No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study , 2015 .
[44] M. Beksac,et al. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications , 2015, Haematologica.
[45] D. Lipsker,et al. Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases , 2015, British journal of haematology.
[46] K. Kashani,et al. Crystalglobulin-induced nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.
[47] E. Hod,et al. New perspectives on the thrombotic complications of haemolysis , 2015, British journal of haematology.
[48] M. Giacca,et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. , 2015, Exercise immunology review.
[49] J. Eustace,et al. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma , 2015, Journal of Thrombosis and Thrombolysis.
[50] D. Kenny,et al. Platelet hyporeactivity in active myeloma. , 2014, Thrombosis research.
[51] J. George,et al. Syndromes of thrombotic microangiopathy. , 2014, The New England journal of medicine.
[52] G. Parry,et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. , 2014, Blood.
[53] I. Weitz. Complement the hemostatic system: an intimate relationship. , 2014, Thrombosis research.
[54] V. De Stefano,et al. Venous Thromboembolism in Multiple Myeloma , 2014, Seminars in Thrombosis & Hemostasis.
[55] Michele Cavo,et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] M. Drayson,et al. How I treat monoclonal gammopathy of renal significance (MGRS). , 2013, Blood.
[57] G. Leone,et al. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients , 2013, British journal of haematology.
[58] X. Mariette,et al. The Spectrum of Type I Cryoglobulinemia Vasculitis , 2013, Medicine.
[59] P. Cacoub,et al. Cryoglobulinemia vasculitis: an update , 2013, Current opinion in rheumatology.
[60] H. Kwaan. Hyperviscosity in plasma cell dyscrasias. , 2013, Clinical hemorheology and microcirculation.
[61] M. Shima,et al. Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein κ-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody , 2012, Annals of Hematology.
[62] Yongbo Huang,et al. Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis. , 2012, Thrombosis research.
[63] S. Berentsen,et al. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. , 2012, Blood reviews.
[64] A. Gabrielli,et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. , 2012, Arthritis and rheumatism.
[65] M. Boccadoro,et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. , 2012, Blood.
[66] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[67] E. Zamagni,et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. , 2011, Seminars in thrombosis and hemostasis.
[68] H. Sørensen,et al. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism , 2011, European journal of haematology.
[69] M. Björkholm,et al. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. , 2011, Seminars in hematology.
[70] P. Ravaud,et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry , 2010, Arthritis care & research.
[71] E. Zamagni,et al. Thalidomide–dexamethasone as up‐front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low‐dose warfarin , 2010, European journal of haematology.
[72] B. Barlogie,et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.
[73] C. Hofmeister,et al. TTP disease course is independent of myeloma treatment and response , 2010, American journal of hematology.
[74] A. Cohen,et al. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. , 2010, Thrombosis research.
[75] P. Sonneveld,et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. , 2009, Blood.
[76] U. Mellqvist,et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. , 2009, Blood.
[77] L. Cornell,et al. A case of bilateral renal arterial thrombosis associated with cryocrystalglobulinaemia , 2009, NDT plus.
[78] D. Sène,et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. , 2009, The American journal of medicine.
[79] I. Jaiyesimi,et al. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. , 2009, Clinical advances in hematology & oncology : H&O.
[80] T. Therneau,et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. , 2009, Mayo Clinic proceedings.
[81] R. Hayes,et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.
[82] U. Mellqvist,et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. , 2008, Blood.
[83] P. Sonneveld,et al. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. , 2007, Clinical lymphoma & myeloma.
[84] P. Sonneveld,et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. , 2007, Haematologica.
[85] C. Eby. Bleeding and thrombosis risks in plasma cell dyscrasias. , 2007, Hematology. American Society of Hematology. Education Program.
[86] J. Gotlib,et al. A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance , 2006, American journal of hematology.
[87] B. Barlogie,et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism , 2006, British journal of haematology.
[88] K. Beiske,et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. , 2006, Haematologica.
[89] M. Gladwin,et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.
[90] A. Pereira,et al. Anti-Sa cold agglutinin of IgA class requiring plasma-exchange therapy as early manifestation of multiple myeloma , 1993, Annals of Hematology.
[91] P. Vos,et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[92] Gordan Srkalovic,et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease , 2004, Cancer.
[93] T. Amdo,et al. An approach to the diagnosis and treatment of cryofibrinogenemia. , 2004, The American journal of medicine.
[94] J. Nojima,et al. A non‐immunological phospholipid‐dependent coagulation inhibitor associated with IgGλ‐type multiple myeloma , 2004, American journal of hematology.
[95] J. Schölmerich,et al. A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody , 2002, Rheumatology International.
[96] B. Barlogie,et al. Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[97] K. Konstantopoulos,et al. Detection of CD55- and/or CD59-Deficient Red Cell Populations in Patients With Plasma Cell Dyscrasias , 2002, International journal of hematology.
[98] Felicia A Tucci,et al. The cryoglobulins: an overview , 2001, European journal of clinical investigation.
[99] O. Chosidow,et al. Cryofibrinogenaemia: a study of 49 patients , 2000, Clinical and experimental immunology.
[100] P. Thiagarajan,et al. Light‐chain paraproteins with lupus anticoagulant activity , 1999, American journal of hematology.
[101] W M O'Fallon,et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.
[102] E. Christophers,et al. Monoclonal cryo-antifibrinogenemia. , 1996, Arthritis and rheumatism.
[103] J. Erban,et al. Acquired free protein S deficiency associated with multiple myeloma: A case report , 1996, American journal of hematology.
[104] I. Emura,et al. Crystalglobulin‐induced vasculopathy accompanying ischemic intestinal lesions of a patient with myeloma , 1996, Pathology international.
[105] R. Ng,et al. Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance. , 1994, American journal of clinical pathology.
[106] R. Tait,et al. Waldenström's macroglobulinaemia secreting a paraprotein with lupus anticoagulant activity: possible association with gastrointestinal tract disease and malabsorption. , 1993, Journal of clinical pathology.
[107] N. Ball,et al. Crystalglobulinemia syndrome. A manifestation of multiple myeloma , 1993, Cancer.
[108] B. Sokołowska,et al. [Disorders of blood platelet homeostasis in patients with multiple myeloma before the treatment and during remission]. , 1990, Polskie Archiwum Medycyny Wewnetrznej.
[109] L. Silberstein,et al. Cold hemagglutinin disease associated with IgG cold-reactive antibody. , 1987, Annals of internal medicine.
[110] W. Tyminski,et al. Disturbances of platelet function in patients with multiple myeloma. , 1987, Folia haematologica.
[111] G. Blaskó,et al. Functional deficiency of protein C and skin necrosis in multiple myeloma. , 1986, Thrombosis research.
[112] E. Reece,et al. Spontaneous factor XI inhibitors. Seven additional cases and a review of the literature. , 1984, Archives of internal medicine.
[113] D. Karamanolis,et al. Characterization of Cryofibrinogen Isolated from Patients Plasma , 1979, Thrombosis and Haemostasis.
[114] P. Castaldi,et al. Inflammation and Haemostasis in Paraproteinaemias , 1971, British journal of haematology.
[115] A. De Vries,et al. Plasma cell myeloma associated with an unusual myeloma protein causing impairment of fibrin aggregation and platelet function in a patient with multiple malignancy. , 1970, The American journal of medicine.
[116] E. M. Vigliano,et al. Bleeding syndrome in a patient with IgA myeloma: interaction of protein and connective tissue. , 1967, Blood.